Sugi Predict

Sugi Predict / Targets / CBFB

CBFB

Core-binding factor subunit beta · Q13951 · CBFB on Sugi Atlas →

12,896 patent compounds predicted against CBFB, 7,431 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL124222 SCHEMBL124222 1.00 16/20
SCHEMBL124333 SCHEMBL124333 1.00 15/20
SCHEMBL179143 SCHEMBL179143 0.81 14/20
SCHEMBL179154 SCHEMBL179154 0.72 14/20
SCHEMBL124228 SCHEMBL124228 1.00 13/20
SCHEMBL124230 SCHEMBL124230 1.00 13/20
SCHEMBL124264 SCHEMBL124264 1.00 13/20
SCHEMBL179151 SCHEMBL179151 1.00 13/20
SCHEMBL124377 SCHEMBL124377 0.81 13/20
SCHEMBL125118 SCHEMBL125118 0.80 13/20
SCHEMBL124273 SCHEMBL124273 0.68 13/20
SCHEMBL124272 SCHEMBL124272 0.68 13/20
SCHEMBL179142 SCHEMBL179142 0.68 13/20
SCHEMBL179149 SCHEMBL179149 0.61 13/20
SCHEMBL125187 SCHEMBL125187 1.00 12/20
SCHEMBL125154 SCHEMBL125154 0.93 12/20
SCHEMBL125825 SCHEMBL125825 0.81 12/20
SCHEMBL124343 SCHEMBL124343 0.80 12/20
SCHEMBL124265 SCHEMBL124265 0.78 12/20
SCHEMBL124267 SCHEMBL124267 0.78 12/20

Clinical trials — most relevant to CBFB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) PHASE3COMPLETED
Timed-Sequential Induction in CBF-AML PHASE3COMPLETED
Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia PHASE3UNKNOWN
Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1) PHASE2UNKNOWN
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) PHASE1/PHASE2RECRUITING
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, 7+3) for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) PHASE2RECRUITING
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT PHASE2RECRUITING
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia PHASE2COMPLETED
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia PHASE2COMPLETED
A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia PHASE1/PHASE2RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment PHASE2COMPLETED
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE2COMPLETED
Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) PHASE1/PHASE2COMPLETED
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML PHASE2UNKNOWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib PHASE2COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia nanCOMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia nanUNKNOWN
Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse. nanUNKNOWN
Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor nanCOMPLETED
Haplo-Cord HSCT for AML/MDS nanRECRUITING
Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia nanCOMPLETED
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient nanRECRUITING
Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients nanNOT_YET_RECRUITING
The Efficacy of Allo-HSCT in ND HR-CBF-AML nanRECRUITING
EKLF Gene Expression in β-thalassemia nanNOT_YET_RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CBFB binder may also engage these)

ProteinNameSimilarity
Q08024 — 1.000 Q08024 →
Q20PL8 — 0.997 Q20PL8 →
O36384 — 0.995 O36384 →
P08274 — 0.995 P08274 →
O92564 — 0.995 O92564 →
Q6J871 — 0.995 Q6J871 →
P69278 — 0.994 P69278 →
A4GCJ2 — 0.994 A4GCJ2 →
B2I786 — 0.994 B2I786 →
Q8QPI8 — 0.994 Q8QPI8 →
O68951 — 0.994 O68951 →
B4SVW1 — 0.994 B4SVW1 →
Q6J880 — 0.994 Q6J880 →
O41665 — 0.994 O41665 →
Q8X7N6 — 0.994 Q8X7N6 →
Q9YPE8 — 0.994 Q9YPE8 →
P08270 — 0.994 P08270 →
Q95ZL9 — 0.994 Q95ZL9 →
A9NA93 — 0.994 A9NA93 →
P03496 — 0.993 P03496 →
Q24040 — 0.993 Q24040 →
Q96912 — 0.993 Q96912 →
Q134L8 — 0.993 Q134L8 →
P08463 — 0.993 P08463 →
Q3YPY9 — 0.993 Q3YPY9 →
Q6DP62 — 0.993 Q6DP62 →
Q0PDM0 — 0.993 Q0PDM0 →
B1Y708 — 0.993 B1Y708 →
Q9D211 — 0.993 Q9D211 →
Q5P796 — 0.993 Q5P796 →